Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Cancer Type, By End Use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes, Others), By Region, And Segment Forecasts, 2023 To 2030

MRD testing is essentially used in clinical and research applications for the detection of a residual disease condition. These tests are used for the detection of either hematological malignancies or solid tumors. Continuous monitoring of residual cancer cells throughout the core treatment and during the remission stage fetches the oncologists with personalized insights on the efficacy of the used therapy. It also precisely predicts the risk of a possible relapse of the condition. MRD testing influences treatment choices to yield better therapeutic outcomes.

The use of MRD testing as a novel prognostic and diagnostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. It generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. For instance, in February 2022, the Foundation for National Institutes of Health’s Biomarkers Consortium launched a project for the validation of novel detection and quantification methods to effectively detect the trace amounts of carcinogenic cells left out in the body after a full-fledged anti-cancer therapy, and in cases of acute myeloid leukemia.

Measurement of therapeutic outcomes are critical for the successful adoption of a given cancer therapeutic regime. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK’s hematology therapeutics.

Surgical removal of a tumor with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can still remain in the body parts and bloodstream. The diagnosis of such residual cells are crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a ‘software-as-a-medical-device’ MRD test in Europe.

Potential MRD diagnostics play a crucial role to make effective individual and long-term clinical decisions after the core cancer therapy. Moreover, MRD diagnostics efficiency is also important for healthcare insurance companies to effectively offer financial assistance to cancer survivors across the globe. For instance, in November 2021, Palmetto GBA's Molecular Diagnostics Program (MolDX) determined a medical expense cover that supported patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and B-cell acute lymphoblastic leukemia (ALL) for effectively monitoring the presence of residual cancer cells using the clonoSEQ platform.

Numerous MRD tests for the detection of residual solid tumors require tissue biopsy samples and deployment of patient-specific assays, which consumes longer turn-around time. Therefore, blood sample-based MRD detection assays are preferred. For instance, in January 2021 GRAIL, Inc., signed into a collaboration with Amgen, AstraZeneca, and Bristol Myers Squibb for evaluation of its MRD detection technology that is based on methylation.

Cancer therapeutics are effectively moderated to avoid leaving a residue of tumorous cells using the most relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are rising the need for consideration of individual genetic characteristics for effective treatment. For instance, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera’s diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

Minimum Residual Disease (MRD) Market: Segmentation

Some of the key companies operating in the market include Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Arup Laboratories, F. Hoffmann- La Roche Ltd, Cergentis B.V., Guardant Health, ICON plc, Laboratory Corporation of America Holdings, Invivoscribe, Inc., Mission Bio, Inc., Opko Health, Natera, Inc., NeoGenomics Laboratories, Inc., Sysmex Corporation, Quest Diagnostics Incorporated,